Novo Nordisk in deal with Upsher-Smith to market new dose Vagifem in USA
Danish drugmaker Novo Nordisk says that it has signed an exclusive agreement with Upsher-Smith Laboratories to market Vagifem (estradiol vaginal tablets) 10mcg. Under the terms of the deal, financial details of which were not disclosed, Upsher-Smith is exclusively marketing Vagifem 10mcg to physicians in the USA beginning August 2 through the company's existing field sales force.
Novo Nordisk introduced Vagifem 10mcg to the US market earlier this year. The new dose replaces Vagifem 25mcg dose, which was discontinued on July 30 this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze